kotak-logo
Wanbury Share Price

Wanbury Share Price

251.25
+1.25 (0.50%)
WANBURY • 06 Mar, 2026 | 03:29 PM

1Y Annualised Return

26.49%

3Y Annualised Return

89.70%

5Y Annualised Return

20.95%

10Y Annualised Return

18.87%

Wanbury Stock Performance

1W Return-5.41
1Y Return27.13
Today's Low242.35
Prev. Close250.00
Mkt Cap (Cr.)877.85
1M Return2.44
3Y Return562.93
52-Week High329.7
Open242.35
PE Ratio13.51
6M Return-9.91
Today's High253.95
52-Week Low161.5
Face Value10

Wanbury Company background

Founded in: 1988
Wanbury Limited, formerly known Pearl Organics Limited was incorporated in August, 1988. The Company attained its present name in September 2004. The Company is engaged in the business of pharmaceutical and related activities, including research.The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs. In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga. In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US.In 200708, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007. Pursuant to the aforesaid Order of the Honble Bl FR 7,85,557 Equity Shares of face value of Rs. 10/ each of the Company were issued to the Equity Shareholders of DOCL on 17th March, 2008. Similarly, the Pharmaceutical Products of India Limited (PPIL) was merged with the Company effective from April 1, 2006. In terms of the said Scheme of Merger, the Company had issued 5,62,618 Equity Shares of face value of Rs. 10/ each to the Equity Shareholders of PPIL on 27 June, 2007, which got listed on Bombay Stock Exchange Limited and National Stock Exchange Limited respectively.The company entered into a strategic association with Bravo Healthcare Ltd and incorporated Ningxia Wanbury Fine Chemicals Co Ltd to source raw materials from China. It opened its office in Zurich,Switzerland for its CRAMS business and incorporated Wanbury Global FZE in Middle East for carrying out its trading activities in the year 2008.The novel product Cdense Gems was launched in May, 2008. The Company completed the restructuring of the Formulation Division during the year 2013. It launched, MyotolF, targeted at female infertility in 2013, it launched Folinine. The Companys newly launched products MyotolF (to treat polycystic ovarian syndrome) and CalK2 (in prevention and management of Osteoporosis) were labelled as one of the best launches in 2014.

Wanbury Financial Highlights


For the full year FY2025–2026, revenue reached ₹603.01 crore and profit touched at ₹30.53 crore.

Wanbury Share Price Today


As of 7 Mar 2026, Wanbury share price is ₹251.2. The stock opened at ₹242.4 and had closed at ₹250 the previous day. During today’s trading session, Wanbury share price moved between ₹242.35 and ₹253.95, with an average price for the day of ₹248.15. Over the last 52 weeks, the stock has recorded a low of ₹161.50 and a high of ₹329.70. In terms of performance, Wanbury share price has declined by 9.9% over the past six months and has increased by 26.49% over the last year.
Read More
Wanbury SIP Return Calculator
5,000
Over the past
Total Investment of ₹3,00,000
Monthly SIP of 5,000 would have become 5,31,759 in 5 years with a gain of 2,31,759 (+77.25%)
View details of Market Depth

Wanbury Fundamental

Market Cap (in crs)

877.85

Face Value

10

Turnover (in lacs)

45.17

Key Metrics

Qtr Change %
55.57% Gain from 52W Low
5.2
Dividend yield 1yr %
0

Wanbury Key Financials

View more
Loading chart...
Wanbury Quarterly Revenue
Wanbury Yearly Revenue
Wanbury Quarterly Net Profit/Loss
Wanbury Yearly Net Profit/Loss

Wanbury Result Highlights

  • Wanbury Ltd reported a 16.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 23.8%.

  • Its expenses for the quarter were up by 13.6% QoQ and 14.4% YoY.

  • The net profit decreased 59.9% QoQ and increased 1197.1% YoY.

  • The earnings per share (EPS) of Wanbury Ltd stood at 4 during Q1 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Wanbury Technical Analysis

Moving Averages Analysis
251.25
Current Price
Bullish Moving Averages
8
Bearish Moving Averages
8
Day EMA5
252.60
Day EMA10
255.00
Day EMA12
255.00
Day EMA20
252.30
Day EMA26
249.60
Day EMA50
243.10
Day EMA100
242.30
Day EMA200
243.90
Delivery & Volume
Loading chart...

Day

100.00%

Week

100.00%

Month

61.00%

Delivery & Volume

249.18
Pivot
Resistance
First Resistance
256.02
Second Resistance
260.78
Third Resistance
267.62
Support
First Support
244.42
Second support
237.58
Third Support
232.82
Relative Strength Index
51.15
Money Flow Index
60
MACD
5.45
MACD Signal
8.46
Average True Range
15.15
Average Directional Index
21.84
Rate of Change (21)
-2.77
Rate of Change (125)
-9.51
Compare

Wanbury Shareholding Pattern

Promoter
43.1%
Foreign Institutions
0.7%
Public
56.2%

Wanbury Latest News

09 FEB 2026 | Monday
06 FEB 2026 | Friday
05 FEB 2026 | Thursday

Please be aware that Wanbury stock prices are subject to continuous fluctuations due to various factors.